How the price of Lil­ly's weight man­age­ment drug could fu­el its ri­val­ry with No­vo Nordisk

Eli Lil­ly’s high­ly an­tic­i­pat­ed weight loss ri­val Zep­bound is set to hit shelves this year at a steep dis­count to No­vo Nordisk’s We­govy and with per­haps bet­ter ef­fi­ca­cy, set­ting the stage for a fierce com­pe­ti­tion over ac­cess and sup­ply.

Zep­bound, which re­ceived FDA ap­proval on Wednes­day, is priced at $1,059.87 per month, which Lil­ly says is a 20% dis­count to We­govy’s 2.4 mg in­jec­tions.

The drug is priced “pret­ty much at par­i­ty” to its type 2 di­a­betes med­ica­tion Moun­jaro, which con­tains the same ac­tive in­gre­di­ent and has a list price of $1,023.04 per fill, said Pa­trik Jon­s­son, in­com­ing pres­i­dent of Lil­ly Di­a­betes and Obe­si­ty, at a UBS event Wednes­day, ac­cord­ing to an Al­phaSense tran­script.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER